Last reviewed 2026-04-19 · How we verify

CD30 CAR-T Cells

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · Phase 1 active Small molecule

CD30 CAR-T Cells is a Small molecule drug developed by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd. It is currently in Phase 1 development.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CD30 CAR-T Cells
Sponsor	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma (PHASE1)
CD30 CAR for CD30+ NSGCT (PHASE2)
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (PHASE1)
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (PHASE1, PHASE2)
GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma (PHASE1, PHASE2)
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (PHASE1)
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (PHASE1, PHASE2)
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CD30 CAR-T Cells CI brief — competitive landscape report
CD30 CAR-T Cells updates RSS · CI watch RSS
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd portfolio CI

Frequently asked questions about CD30 CAR-T Cells

What is CD30 CAR-T Cells?

CD30 CAR-T Cells is a Small molecule drug developed by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.

Who makes CD30 CAR-T Cells?

CD30 CAR-T Cells is developed by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (see full Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd pipeline at /company/shanghai-unicar-therapy-bio-medicine-technology-co-ltd).

What development phase is CD30 CAR-T Cells in?

CD30 CAR-T Cells is in Phase 1.

Manufacturer: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing